Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 14 | 2025 | 478 | 3.750 |
Why?
|
| Cerebrovascular Circulation | 7 | 2023 | 220 | 2.390 |
Why?
|
| Vasodilation | 8 | 2021 | 114 | 2.150 |
Why?
|
| Muscle, Skeletal | 9 | 2025 | 633 | 1.570 |
Why?
|
| Nitric Oxide Synthase | 4 | 2021 | 34 | 1.360 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2021 | 23 | 1.360 |
Why?
|
| Cerebral Arteries | 3 | 2019 | 33 | 1.260 |
Why?
|
| Hand Strength | 7 | 2025 | 38 | 1.130 |
Why?
|
| Forearm | 7 | 2025 | 39 | 1.010 |
Why?
|
| Exercise Test | 4 | 2020 | 248 | 0.980 |
Why?
|
| Cytochrome P-450 CYP2C9 Inhibitors | 1 | 2025 | 3 | 0.960 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2025 | 4 | 0.960 |
Why?
|
| Fluconazole | 1 | 2025 | 9 | 0.960 |
Why?
|
| Vasoconstriction | 1 | 2025 | 45 | 0.940 |
Why?
|
| Sympathetic Nervous System | 1 | 2025 | 68 | 0.930 |
Why?
|
| Boxing | 1 | 2022 | 3 | 0.780 |
Why?
|
| Adult | 19 | 2025 | 7703 | 0.780 |
Why?
|
| Hot Temperature | 1 | 2022 | 87 | 0.740 |
Why?
|
| Cognition | 5 | 2025 | 322 | 0.720 |
Why?
|
| Young Adult | 13 | 2025 | 2714 | 0.710 |
Why?
|
| High-Intensity Interval Training | 1 | 2020 | 9 | 0.700 |
Why?
|
| Executive Function | 1 | 2020 | 25 | 0.690 |
Why?
|
| Regional Blood Flow | 7 | 2025 | 163 | 0.630 |
Why?
|
| omega-N-Methylarginine | 5 | 2021 | 11 | 0.630 |
Why?
|
| Hypoxia | 1 | 2019 | 89 | 0.620 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2017 | 2 | 0.570 |
Why?
|
| Sildenafil Citrate | 1 | 2017 | 4 | 0.570 |
Why?
|
| Female | 19 | 2025 | 15074 | 0.540 |
Why?
|
| Humans | 27 | 2025 | 27968 | 0.520 |
Why?
|
| Male | 20 | 2025 | 13424 | 0.520 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 41 | 0.480 |
Why?
|
| Neurovascular Coupling | 3 | 2022 | 154 | 0.480 |
Why?
|
| Cyclooxygenase Inhibitors | 4 | 2021 | 25 | 0.460 |
Why?
|
| Endothelium, Vascular | 2 | 2025 | 325 | 0.450 |
Why?
|
| Blood Flow Velocity | 4 | 2023 | 64 | 0.430 |
Why?
|
| Oxygen Consumption | 4 | 2019 | 181 | 0.430 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2021 | 74 | 0.410 |
Why?
|
| Blood Pressure | 3 | 2023 | 354 | 0.390 |
Why?
|
| Double-Blind Method | 2 | 2025 | 414 | 0.370 |
Why?
|
| Peripheral Arterial Disease | 2 | 2025 | 137 | 0.360 |
Why?
|
| Hemodynamics | 4 | 2021 | 220 | 0.350 |
Why?
|
| Ventilators, Mechanical | 1 | 2009 | 10 | 0.330 |
Why?
|
| Fires | 1 | 2009 | 12 | 0.330 |
Why?
|
| Caffeine | 1 | 2009 | 39 | 0.320 |
Why?
|
| Ketorolac | 3 | 2021 | 9 | 0.290 |
Why?
|
| Healthy Volunteers | 2 | 2025 | 49 | 0.280 |
Why?
|
| Resistance Training | 2 | 2022 | 212 | 0.270 |
Why?
|
| Middle Cerebral Artery | 2 | 2023 | 48 | 0.250 |
Why?
|
| Lower Body Negative Pressure | 1 | 2025 | 3 | 0.240 |
Why?
|
| Niacinamide | 1 | 2025 | 31 | 0.230 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 134 | 0.230 |
Why?
|
| Sleep Deprivation | 2 | 2021 | 28 | 0.230 |
Why?
|
| NAD | 1 | 2025 | 100 | 0.230 |
Why?
|
| Enzyme Inhibitors | 2 | 2016 | 249 | 0.220 |
Why?
|
| Prefrontal Cortex | 2 | 2021 | 80 | 0.210 |
Why?
|
| Adolescent | 4 | 2020 | 3104 | 0.200 |
Why?
|
| Dietary Supplements | 1 | 2025 | 240 | 0.200 |
Why?
|
| Circulating MicroRNA | 1 | 2022 | 10 | 0.200 |
Why?
|
| Obesity | 2 | 2021 | 667 | 0.200 |
Why?
|
| Rest | 1 | 2023 | 94 | 0.200 |
Why?
|
| Acclimatization | 1 | 2022 | 30 | 0.190 |
Why?
|
| Athletes | 1 | 2022 | 70 | 0.190 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2021 | 55 | 0.190 |
Why?
|
| Sex Factors | 2 | 2020 | 465 | 0.180 |
Why?
|
| Motor Cortex | 1 | 2021 | 48 | 0.180 |
Why?
|
| Citrulline | 1 | 2020 | 3 | 0.170 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2021 | 19 | 0.170 |
Why?
|
| Isoproterenol | 2 | 2021 | 23 | 0.170 |
Why?
|
| Menstrual Cycle | 1 | 2020 | 23 | 0.170 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 79 | 0.170 |
Why?
|
| Indomethacin | 1 | 2019 | 15 | 0.170 |
Why?
|
| Random Allocation | 1 | 2019 | 151 | 0.160 |
Why?
|
| Brain | 2 | 2021 | 739 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2022 | 294 | 0.150 |
Why?
|
| Heart Rate | 1 | 2020 | 379 | 0.150 |
Why?
|
| Brachial Artery | 2 | 2019 | 36 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 756 | 0.150 |
Why?
|
| Oxygen | 1 | 2019 | 232 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 263 | 0.150 |
Why?
|
| Muscle Strength | 2 | 2021 | 230 | 0.150 |
Why?
|
| Cyclic GMP | 1 | 2017 | 29 | 0.140 |
Why?
|
| Aging | 2 | 2022 | 968 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 22 | 0.120 |
Why?
|
| Vascular Resistance | 1 | 2015 | 50 | 0.120 |
Why?
|
| Ascorbic Acid | 1 | 2014 | 24 | 0.110 |
Why?
|
| Muscle Contraction | 1 | 2015 | 170 | 0.110 |
Why?
|
| Biochemical Phenomena | 1 | 2014 | 2 | 0.110 |
Why?
|
| Middle Aged | 5 | 2025 | 7111 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2016 | 173 | 0.110 |
Why?
|
| Sex Characteristics | 1 | 2015 | 172 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2015 | 240 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 78 | 0.110 |
Why?
|
| Fatigue | 1 | 2014 | 64 | 0.110 |
Why?
|
| Exercise Tolerance | 1 | 2014 | 82 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 300 | 0.110 |
Why?
|
| Antioxidants | 1 | 2014 | 223 | 0.100 |
Why?
|
| Aged | 4 | 2025 | 5383 | 0.080 |
Why?
|
| Ergonomics | 1 | 2009 | 2 | 0.080 |
Why?
|
| Perfusion | 2 | 2021 | 43 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 2 | 2016 | 5 | 0.060 |
Why?
|
| Pyridinium Compounds | 1 | 2025 | 27 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2025 | 188 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 817 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2025 | 430 | 0.050 |
Why?
|
| Postmenopause | 1 | 2022 | 83 | 0.050 |
Why?
|
| Vibration | 1 | 2022 | 78 | 0.050 |
Why?
|
| Arterioles | 1 | 2022 | 61 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 11 | 0.050 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2021 | 24 | 0.050 |
Why?
|
| Mitochondria | 1 | 2025 | 369 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 44 | 0.050 |
Why?
|
| Animals | 1 | 2015 | 10370 | 0.050 |
Why?
|
| Reaction Time | 1 | 2021 | 94 | 0.050 |
Why?
|
| Knee | 1 | 2021 | 25 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2021 | 59 | 0.050 |
Why?
|
| Memory, Short-Term | 1 | 2021 | 62 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 1590 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 152 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 134 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2025 | 667 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 2015 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2021 | 201 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 719 | 0.040 |
Why?
|
| Neurons | 1 | 2021 | 282 | 0.040 |
Why?
|
| Diffusion | 1 | 2019 | 39 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 22 | 0.030 |
Why?
|
| Microcirculation | 1 | 2016 | 112 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 95 | 0.030 |
Why?
|
| Lower Extremity | 1 | 2015 | 84 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2014 | 9 | 0.030 |
Why?
|
| Dementia | 1 | 2016 | 90 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 92 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 118 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 733 | 0.030 |
Why?
|
| Motor Activity | 1 | 2014 | 148 | 0.030 |
Why?
|
| Models, Biological | 1 | 2016 | 466 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 165 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 680 | 0.020 |
Why?
|